Diagnostic Enzymes Market: Current Analysis and Forecast (2022-2028)

Enzymes are proteins with highly specialized catalytic functions, produced by all living organisms. The metabolic activity of all living creatures, including plants, microbes, animals, and mankind, depends on enzymes. Because of their excellent bio-catalytic properties, enzymes are frequently used in the detection of numerous disorders. Several metabolic problems can be caused by enzyme abnormalities. As a result, elements of the enzyme metabolism systems have been used as unique markers for the diagnosis of diseases. The prompt control of the transmission of infectious diseases and the reduction of the dangers to public health depends on the adoption of proper diagnostic enzyme techniques. Therefore, the rising prevalence of various infectious & chronic diseases is one of the major factors responsible for the growth of the diagnostic enzymes market. For instance, as per the World Health Organization 2020, the global impact of infectious disease by the SARS-CoV-2 outbreak (COVID-19), caused over 13.3 million infections and 782,000 deaths globally.

The Diagnostic Enzymes Market is expected to grow at a steady rate of around 4% owing to the increasing adoption of enzyme-based diagnostic tests coupled with the growing innovations in diagnostics technologies. Major players in the market offer innovative developments in the biotechnology domain with technologically advanced features. For instance, in January 2021, Creative Enzymes launched a complete product portfolio of diagnostic enzymes for medical and research diagnosis.

Based on type, the diagnostic enzymes market is segmented into Taq polymerase, RNase inhibitors, cas9 enzyme, acid phosphatase, glucose oxidase/glucose dehydrogenase, urease, lactate oxidase, and others. The glucose oxidase/glucose dehydrogenase segment accounted for a significant market share in 2020 owing to its several advantages such as its abundance, biocompatibility, and lack of toxicity. Furthermore, the entry of global players into emerging markets adds to the growth of the market during the forecast period.

On the basis of application, the diagnostic enzymes market is segmented into infectious diseases, autoimmune diseases, oncology, cardiology, nephrology, diabetes, and others. Among these, the infectious diseases segment to hold a significant share of the market in 2020. This is mainly due to the rising incidence of infectious diseases, that require early detection using these enzymes. For instance, according to the CDC/National Center for Health Statistics, 2022, the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis in the US was 3.4 million. Therefore, infectious diseases such as typical pneumonia, TB, streptococcal pharyngitis, ulcerative urogenital infections, and a number of chronic conditions can be easily diagnosed with enzyme-based techniques like PCR.

Based on product type, the diagnostic enzymes market has been classified into molecular enzymes and clinical enzymes. The molecular enzymes category holds a major share of the market during the forecast period. This is mainly due to the rising research and adoption of molecular enzymes in molecular diagnostics. Different enzymes are mostly used through methods like PCR tests, NGS assays, and others. One of the most used molecular biology methods is PCR. The technology is being used more and more in a variety of industries, such as cloning, sequencing, forensic investigation, and diagnostic testing.

For a better understanding of the market adoption of the Diagnostic Enzymes industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increased need for enzymes and the rising incidence of infectious diseases in the region which has become dominant. In order to combat the continuing epidemic, the FDA has approved COVID-19 laboratory-developed diagnostics for emergency use. The majority of these emergency usage authorizations also make use of RT-PCR-based testing and enzyme-linked immunosorbent assays for the identification of SARS-CoV-2. The creation of such tests is anticipated to be profitable in the North American market because of the high usage of enzymes during RT-PCR.

Some of the major players operating in the market include: Takara Bio, Inc., Promega Corporation, Enzo Life Sciences, Inc., Merck KGaA, Thermo Fisher Scientific, Inc., Creative Enzymes, F. Hoffmann-La Roche Ltd., Solis BioDyne, Ampliqon A/S, and Genzyme Corporation